Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research report released on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright started coverage on Affimed in a research note on Monday, December 12th. They issued a buy rating and a $6.00 target price for the company. Piper Sandler reduced their price objective on Affimed from $7.00 to $6.00 and set an overweight rating for the company in a research report on Monday, December 12th. Wells Fargo & Company reduced their price objective on Affimed from $8.00 to $7.00 and set an overweight rating for the company in a research report on Monday, December 12th. SVB Leerink reduced their price objective on Affimed from $10.00 to $6.00 and set an outperform rating for the company in a research report on Monday, December 12th. Finally, Truist Financial reduced their target price on Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $5.83.

Affimed Trading Down 1.9 %

NASDAQ AFMD opened at $0.76 on Thursday. Affimed has a fifty-two week low of $0.74 and a fifty-two week high of $5.10. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.63 and a current ratio of 5.65. The stock has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.58. The stock has a market cap of $93.80 million, a P/E ratio of -1.21 and a beta of 2.58.

Hedge Funds Weigh In On Affimed

Several large investors have recently made changes to their positions in the business. Alliancebernstein L.P. lifted its position in shares of Affimed by 25.6% in the fourth quarter. Alliancebernstein L.P. now owns 165,000 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 33,600 shares in the last quarter. Millennium Management LLC increased its stake in Affimed by 105.7% during the fourth quarter. Millennium Management LLC now owns 2,057,347 shares of the biopharmaceutical company’s stock worth $2,551,000 after acquiring an additional 1,057,330 shares during the last quarter. Morgan Stanley increased its stake in Affimed by 345.1% during the fourth quarter. Morgan Stanley now owns 2,109,471 shares of the biopharmaceutical company’s stock worth $2,616,000 after acquiring an additional 1,635,580 shares during the last quarter. Man Group plc increased its stake in Affimed by 225.9% during the fourth quarter. Man Group plc now owns 163,608 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 113,408 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Affimed during the fourth quarter valued at approximately $813,000. 61.73% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Company Profile

(Get Rating)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.